N/A N=108 The Effects of Gum Chewing on Math Scores in Adolescents
Academic Achievement in Math
Primary: Math Scores on the Texas Assessment of Knowledge and Skills (TAKS) — 65.1; 70.0 percentile
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 Is an Antiplaque Chewing Gum (30 mg) Able to Reduce Dental Plaque in a Healthy Population?
Plaque Regrowth
Primary: Safety, Tolerability and Effectiveness in Reducing Dental Plaque of KLS-W Delivered in a Chewing Gum Formulation — 0; 0; 0; 0 participants
N/A N=56 Effect of Chewing Gum in Hemodialysis Patients
Chewing Gum · Hemodialysis
Primary: Change From Baseline Intradialytic Weight Gain — 2.53; 2.44 kg
Phase 2 N=71 Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
Plaque · Gingivitis
Primary: Safety and Tolerability of KSL-W as Measured by Soft Tissue Erythema, Ulceration and Sloughing (AEs and SAEs) — 2; 1; 4; 2 Participants
Phase 4 N=69 Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis
Gingivitis · Plaque, Dental · Periodontal Diseases
Primary: Degree of Plaque as Assessed by the Turesky Modification of the Quigley-Hein Plaque Index — 0.41; 0.43 score on a scale
Phase 1 N=41 Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients
Post Operative Ileus
Primary: Post-Operative Hospital Stay — 79.93; 72.94 hours — p=0.665
Phase 3 N=52 Highdose Nicotine Patch Therapy for Smokeless Tobacco Use
Smokeless Tobacco Use
Primary: End of Treatment (Week 8) Point Prevalence Abstinence — 11; 6 participants — p=0.05
N/A N=20 Chewing and Oral Processing of Solid Food
Dysphagia
Primary: Number of Chewing Cycles Per Bolus — 22; 15; 15; 28 number of chewing cycles
N/A N=38 Assessing Effects of a Denture Gel on Gum Abrasions
Gum Injury
Primary: Abrasion Assessment (Number) — 3.65; 4.11 number of abrasions
Phase 3 N=322 Nicotine Mouth Film for Craving Relief.
Smoking Cessation
Primary: The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds — -14.15; -9.26 mm — p=0.0141
N/A N=10,069 Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi
Preterm Birth · Periodontal Disease · Caries, Dental
Primary: Rate of Preterm Birth — 878; 549 Participants — p=<0.05
Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
N/A N=15 Factors Controlling the Formation of Salivary Films
Healthy
Primary: Impact of Ingredients on Thickness (Depth, nm) of Salivary Films Adsorbed Onto Solid Surfaces — 27 nm
Phase 1 N=100 Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Safety Issues
Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale
Phase 3 N=1,107 Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study
Gastroesophageal Reflux Disease · Dyspepsia
Primary: Change From Baseline in Reflux Disease Questionnaire (RDQ) Scores for the GERD Dimension — -1.27; -1.06 score on a scale — p=<0.0001
Phase 1 N=84 Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations
Smoking Cessation
Primary: Area Under the Curve From Time 0 to Time 't' [AUC(0-t)] of Nicotine 2 mg Test and Reference Product — 11.49; 10.24 hr*ng/mL
N/A N=369 Cessation in Non-Daily Smokers
Smoking
Primary: Smoking Cessation, Continuous 6-month Abstinence — 13; 10 Participants — p=0.46
N/A N=25 Exploratory Study on Effect of Whitening Agent With Emulsion Gel in Xerostomic Population
Xerostomia
Primary: Subjective Perception of Mouth Dryness — 6.92; 6.46; 4.21; 3.46 units on a scale — p=.45
Phase 3 N=270 Nicotine Lozenges for Treatment of Smokeless Tobacco Addiction
Smokeless Tobacco Use
Primary: Prolonged Smokeless Tobacco Abstinence at 3 Months — 65; 41 Participants — p=<0.05
Phase 2 N=60 Green Tea Lozenges for the Management of Dry Mouth
Xerostomia · Sjogren Syndrome · Dry Mouth
Primary: Change in Salivary Flow From Baseline — 0.17; 0.10; 0.66; 0.04 ml/min
Phase 4 N=112 Chewed Versus Integral Pill of Ticagrelor
Percutaneous Coronary Intervention
Primary: Concentration of Pharmacodynamics — 142.5; 210 platelet reaction units
Phase 2 N=120 Provoked Craving Relief Study by NRT
Smoking Cessation
Primary: Mean Change From Baseline in Nicotine Craving Score on a VAS — -11.3; -1.7; -4.6; -28.2 Score on a scale
Phase 3 N=40 Efficacy of Eco-Friendly Toothpaste Tablets Versus Conventional Toothpaste Using PI and GI Index
Gingival Inflammation
Primary: Plaque Index Score at Baseline — 2.80; 2.78 Score on a scale
N/A N=253 Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease
Gingivitis
Primary: Number of Bleeding Sites at Week 12 — 42.02; 67.36 number of bleeding sites — p=<0.0001
Phase 2 N=110 A Proof-of-principle Clinical Study Investigating the Efficacy of an Experimental Dentifrice Containing Sodium Bicarbonate and Sodium Hyaluronate on Gingivitis
Gingivitis
Primary: Number of Bleeding Sites at 6 Weeks (Comparison of Experimental Versus Negative Control Dentifrice) — 9.5; 20.5 Number of Sites — p=<0.0001
Phase 3 N=45 Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients
Gastroesophageal Reflux Disease
Primary: Percentage of Time During the 4-hour Post-dosing Period With pH Below pH 4 — 5.14; 14.94 percentage of time with pH below pH 4 — p=0.0003
Phase 3 N=45 Comparing NicoBloc to Nicotine Lozenges
Smoking Cessation · Nicotine Dependence
Primary: The Treatment Satisfaction Survey — 63.62; 64.67 score on a scale
N/A N=23 A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Denture Adhesive
Denture Retention
Primary: Area Over Baseline Over 12 Hours (AOB0-12) for Test Adhesive 1 Versus (vs.) No Adhesive — 2.09; 1.43 lbs — p=0.1770
N/A N=53 Use of Two Dissolvable Therapeutics Under Removable Partial Dentures
Edentulous Jaw · Edentulous Mouth
Primary: Change From Baseline in Patient Comfort for as Assessed by Numerical Scale. — 0.99; 1.16 units on a scale
Early Phase 1 N=24 Effects of Flavors on Nicotine Reinforcement in Smokers
Nicotine Dependence
Primary: The Reinforcing Drug Effects Will be Measured With the Drug Effects Questionnaire (DEQ). — 43.18; 26.22; 25.20; 56.00 units on a scale